Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals

ABSTRACT

Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 are described,                    
     in which R 1  is substituted C 1 -C 6 -alkyl and C 3 -C 9 -cycloalkyl, R 2 , R 3 , R 4  and R 5  are hydrogen, halogen, nitro, C 1 -C 4 -alkyl, C 1 -C 9 -alkyloxy, substituted C 6 -C 10 -aryl-C 1 -C 4 -alkyloxy, C 6 -C 10 -aryloxy, C 6 -C 10 -aryl, C 3 -C 8 -cycloalkyl or O—C 3 —C 8 -cycloalkyl, or 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR 6 -A-R 7 , with the proviso that R 2 , R 3 , R 4  and R 5  are not simultaneously hydrogen, and at least one of the radicals R 2 , R 3 , R 4  or R 5  is the radical 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR 6 -A-R 7 , wherein R 6 =hydrogen, C 1 -C 4 -alkyl or substituted C 6 -C 10 -aryl-C 1 -C 4 -alkyl, A=a single bond, CO n , SO n  or CONH, n=1 or 2, R 7 =hydrogen, substituted C 1 -C 18 -alkyl, C 2 -C 18 -alkenyl, C 6 -C 10 -aryl-C 1 -C 4 -alkyl, C 5 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 5 -C 8 -cycloalkyl, C 6 -C 10 -aryl-C 2 -C 6 -alkenyl, C 6 -C 10 -aryl, biphenylyl, biphenylyl-C 1 -C 4 -alkyl, indanyl, or the group Het-(CH 2 ) r —, wherein r=0, 1, 2 or 3 and Het=a saturated or unsaturated 5-7-membered heterocycle, which may be optionally benzo-fused and optionally substituted, and proceses for their preparation. The compounds of formula 1 show an inhibitory effect on hormone-sensitive lipase, HSL.

This invention relates to substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, which show an inhibitory effect on hormone-sensitive lipase (HSL), and their pharmaceutically acceptable salts or acid addition salts. The present invention further relates to processes for the preparation of 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, to the use of 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their pharmaceutically acceptable salts or acid addition salts as pharmaceuticals, including their use as inhibitors of HSL, and to pharmaceutical compositions comprising 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their pharmaceutically acceptable salts or acid addition salts, including their use in the treatment of non-insulin dependent diabetes mellitus and diabetic syndrome.

Certain 5-alkoxy-1,3,4-oxadiazol-2-ones substituted with an ortho-substituted phenyl ring or with fused-on five- or six-membered rings have anthelmintic (DE-A 26 04 110) and insecticidal effects (DE-A 26 03 877, EP-B 0 048 040, EP-B 0 067 471).

Certain 5-phenoxy-1,3,4-oxadiazol-2-ones with an ortho-substituted phenyl ring as substituents show an endoparasiticidal effect (EP-A 0 419 918).

An aim of the invention was to find compounds which show an inhibitory effect on hormone-sensitive lipase, HSL.

The present invention relates to substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1:

in which:

R¹ is C₁-C₆-alkyl, C₃-C₉-cycloalkyl, wherein both groups are optionally substituted one or more times by phenyl, C₁-C₄-alkyloxy, S—C₁—C₄-alkyl, N(C₁-C₄-alkyl)₂, and wherein phenyl is optionally substituted one or more times by halogen, C₁-C₄-alkyl, C₁-C₄-alkyloxy, nitro, CF₃; and

R², R³, R⁴ and R⁵ independently of one another are hydrogen, halogen, nitro, C₁-C₄-alkyl, C₁-C₉-alkyloxy; C₆-C₁₀-aryl-C₁-C₄-alkyloxy, C₆-C₁₀-aryloxy, C₆-C₁₀-aryl, C₃-C₈-cycloalkyl or O—C₃-C₈-cycloalkyl, each of which is optionally substituted once, twice or three times by halogen, CF₃, C₁-C₄-alkyloxy or C₁-C₄-alkyl; 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR⁶-A-R⁷, with the proviso that R², R³, R⁴ and R⁵ are not simultaneously hydrogen, and at least one of the radicals R², R³, R⁴ or R⁵ is the radical 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl, or NR⁶-A-R⁷, and wherein:

R⁶ is hydrogen, C₁-C₄-alkyl or C₆-C₁₀-aryl-C₁-C₄-alkyl, wherein aryl may be substituted by halogen, CF₃, C₁-C₈-alkyloxy or C₁-C₄-alkyl;

A is a single bond, CO_(n), SO_(n), or CONH;

n is 1 or 2;

R⁷ is hydrogen, C₁-C₁₈-alkyl or C₂-C₁₈-alkenyl, wherein C₁-C₁₈-alkyl or C₂-C₁₈alkenyl are optionally substituted one to three times by C₁-C₄-alkyl, halogen, CF₃, C₁-C₄-alkyloxy, N(C₁-C₄-alkyl)₂, —COOH, C₁-C₄-alkyloxycarbonyl, C₆-C₁₂-aryl, C₆-C₁₂-aryloxy, C₆-C₁₂-arylcarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy or oxo, wherein aryl is in turn optionally substituted by halogen, C₁-C₄-alkyl, aminosulfonyl or methylmercapto;

C₆-C₁₀-aryl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl, C₆-C₁₀-aryl-C₂-C₆-alkenyl, C₆-C₁₀-aryl, biphenylyl, biphenylyl-C₁-C₄-alkyl, indanyl, each of which is optionally substituted once or twice by C₁-C₁₈-alkyl, C₁-C₁ ₈-alkyloxy, C₃-C₈-cycloalkyl, COOH, hydroxyl, C₁-C₄-alkylcarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, C₆-C₁₀-aryloxy, nitro, cyano, C₆-C₁₀-aryl, fluorosulfonyl, C₁-C₆-alkyloxycarbonyl, C₆-C₁₀-arylsulfonyloxy, pyridyl, NHSO₂-C₆-C₁₀-aryl, halogen, CF₃ or OCF₃, wherein alkyl is in turn optionally substituted by C₁-C₄-alkyloxycarbonyl, CF₃ or carboxyl, and aryl is also optionally substituted by halogen, CF₃ or C₁-C₄-alkyloxy;

or the group Het-(CH₂)_(r)—,

wherein r=0, 1, 2 or 3 and Het=a saturated or unsaturated 5-7-membered heterocycle, optionally benzo-fused and optionally substituted by C₁-C₄-alkyl, C₆-C₁₀-aryl, halogen, C₁-C₄-alkyloxy, C₁-C₄-alkyloxycarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkylmercapto or nitro, wherein the benzo-fused aryl is in turn optionally substituted by halogen, C₁-C₄-alkyloxy or CF₃ and the alkyl in arylalkyl is also optionally by methoxy and CF₃,

and their pharmaceutically acceptable salts and acid addition salts.

Said aryl radicals are optionally substituted one or more times by C₁-C₉-alkyl, C₁-C₈-alkyloxy, halogen, and trifluoromethyl. Said cycloalkyl radicals are optionally substituted one or more times by C₁-C₄-alkyl, C₆-C₁₀-aryl, and said alkyl radicals are optionally substituted by hydroxyl, di-C₁-C₄-alkylamino and fluorine. Halogen is fluorine, chlorine, bromine, generally fluorine and chlorine. Alkyl, alkenyl, alkyloxy, etc. are branched or unbranched. The phrase “is optionally substituted” means that the relevant group is or is not substituted.

Pharmaceutically acceptable salts of compounds of the formula 1 include their organic and inorganic salts, as described in Remington's Pharmaceutical Sciences (A. R. Gennard Editor, Mack Publishing Co., Easton, Pa., USA, 17^(th) Ed., p 1418, (1985)). Examples of acidic groups include, inter alia, sodium, potassium, calcium and ammonium salts. Examples of basic groups include, inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid, or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p-toluenesulfonic acid.

Typical compounds of the formula 1 are those in which:

R¹ is C₁-C₄-alkyl; and/or

R⁵ is hydrogen; and/or

R² is hydrogen, halogen, C₁-C₄-alkyl, C₁-C₉-alkyloxy or amino.

Further examples of compounds of the formula 1 are those in which:

R³ is hydrogen, C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, which is optionally substituted in the aryl moiety by halogen, or is NR⁶-A-R⁷ wherein

R⁶=hydrogen or benzyl,

A=single bond and

R⁷=C₆-C₁₀-aryl-C₁-C₄-alkyl, which is optionally substituted by halogen, CF₃, cyano, phenyl-C₁-C₄-alkyloxy, CF₃-phenoxy, C₅-C₈-cycloalkyl or fluorosulfonyloxy;

C₁-C₁₂-alkyl, which is optionally substituted by C₁-C₄-alkyloxy, phenyl, CF₃ or phenyl-C₁-C₄-alkyloxy; C₂-C₁₂-alkenyl;

or the group Het-(CH₂)_(r)—,

wherein r=0 or 1, and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl or halogen.

Additional compounds of the formula 1 are those in which:

R⁴ is hydrogen, 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or C₆-C₁₀-aryl-C₁-C₄-alkyloxy, which is optionally substituted by halogen, and/or: compounds of the formula 1 in which: R⁴ is NR⁶-A-R⁷, wherein

R⁶=hydrogen or methyl,

A=single bond and

R⁷=hydrogen;

C₁-C₁₂-alky, which is optionally substituted once or twice by halogen;

C₂-C₁₈-alkenyl, which is optionally substituted once or twice by C₁-C₄-alkyl or C₁-C₄-alkyloxycarbonyl;

C₆-C₁₀-aryl-C₁-C₄-alky, which is optionally substituted by halogen, C₁-C₆-alkyloxy, CF₃, cyano, C₅-C₆-cycloalkyl, C₁-C₄-alkyloxycarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, wherein aryl is further optionally substituted by halogen or CF₃;

C₅-C₈-cycloalkyl-C₁-C₄-alkyl;

or the group Het-(CH₂)_(r)—,

wherein r=1, 2 or 3 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally substituted by halogen, C₁-C₄-alkyloxy or C₁-C₄-alkyloxycarbonyl, and/or compounds of the formula 1 in which:

R⁴ is NR⁶-A-R⁷, wherein

R⁶=hydrogen,

A=—CO— and

R⁷=C₁-C₁₈-alkyl, which is optionally substituted by halogen, phenyl, phenoxy, phenylcarbonyl or C₁-C₄-alkyloxycarbonyl, wherein phenoxy is optionally substituted by methyl, halogen or methylmercapto;

C₂-C₁₈-alkenyl, which is optionally substituted by C₆-C₁₀-aryl;

C₆-C₁₀-aryl, which is optionally substituted by halogen, C₁-C₈-alkyl, phenyl-C₁-C₄-alkyl, CF₃, OCF₃, fluorosulfonyl, C₁-C₄-alkyloxycarbonyl, phenoxy, wherein aryl is optionally substituted by C₁-C₄-alkyloxy;

C₆-C₁₀-aryl-C₁-C₄-alkyl, wherein alkyl is optionally substituted by methoxy or CF₃ and aryl by halogen;

or the group Het-(CH₂)_(r)—,

wherein r=0 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl, halogen, C₁-C₄-alkyloxy, halophenyl or halobenzylmercapto, wherein benzo-fused aryl is optionally substituted by halogen or methoxy, and/or compounds of the formula 1 in which:

R⁴ is NR⁶-A-R⁷, wherein

R⁶=hydrogen,

A=—CO₂— and

R⁷=C₁-C₁₈-alkyl, which is substituted by CF₃ or phenyl;

C₆-C₁₀-aryl;

C₆-C₁₀-aryl-C₁-C₄-alkyl, which is substituted by C₁-C₄-alkyl, halogen, CF₃ or OCF₃, benzyloxy or phenyl;

or the group Het-(CH₂)_(r)—,

wherein r=0 or 1 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl or benzyl, and/or compounds of the formula 1 in which:

R⁴ is NR⁶-A-R⁷, wherein

R⁶=hydrogen,

A=—SO₂— and

R⁷=C₁-C₆-alky, which is optionally substituted by CF₃;

C₂-C₄-alkenyl, which is optionally substituted by phenyl;

C₆-C₁₀-aryl, which is optionally substituted by C₁-C₆-alkyl, halogen,

C₁-C₄-alkyloxy or benzyl;

biphenylyl-C₁-C₄-alkyl substituted by halogen;

or the group Het-(CH₂)_(r)—,

wherein r=0 and Het=a saturated or unsaturated 5-7-membered heterocycle, and/or compounds of the formula 1 in which:

R⁴ is NR⁶-A-R⁷, wherein

R⁶=hydrogen,

A=—CO—NH— and

R⁷=C₁-C₁₀-alkyl, which is optionally substituted by C₁-C₄-alkyloxycarbonyl, N(C₁-C₄-alkyl)₂ or phenyl, which is in turn optionally substituted by halogen or aminosulfonyl;

C₆-C₁₀-aryl, which is optionally substituted by C₁-C₆-alkyl, C₁-C₆-alkyloxy, C₁-C₆-alkyloxycarbonyl, phenoxy, OCF₃, benzyl or pyridyl, wherein alkyl is optionally substituted by C₁-C₄-alkyloxycarbonyl or carboxyl;

C₅-C₈-cycloalky, which is optionally substituted by hydroxyl, or indanyl;

or the group Het-(CH2)^(r)—,

wherein r=0 or 1 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally substituted by benzyl.

Other typical compounds of the formula 1 are those in which R¹ is methyl.

Representative compounds of the formula 1 are those mentioned in Examples 21, 22, 27, 28, 30 to 34, 36 to 42, 53, 54, 58, 60, 62, 65, 69, 71, 74, 92, 97,107,116,128, 130, 136,139,142,152,166 and 171.

The compounds of the invention have a surprising inhibitory effect on hormone-sensitive lipase, HSL, an allosteric enzyme in adipocytes, which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and for the transfer of fat constituents into the blood stream. Inhibition of this enzyme thus corresponds to an insulin-like effect of the compounds of the invention, which eventually leads to a reduction of free fatty acids in the blood and of blood glucose. Therefore, the compounds of the invention can be employed in the treatment of metabolic disturbances such as, for example, non-insulin-dependent diabetes mellitus, diabetic syndrome, and direct damage to the pancreas.

The compounds of the invention can be prepared in various ways by methods known per se.

For example, substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 can be prepared by reacting hydrazines of the formula 2 with chloroformic esters of the formula 3 or other reactive carbonic ester derivatives, in which R¹, R², R³, R⁴ and R⁵ are as defined above, to give the compounds of the formula 4, which are acylated with phosgene, carbonyldiimidazole, diphosgene or triphosgene, cyclized and converted, where appropriate, by further chemical modification of the radicals R²-R⁵, such as, for example, by reduction of nitro to amino radicals by known processes, and subsequent acylation or alkylation, into compounds of the formula 1. Since acids are usually liberated in these reactions, neutralization is advisable by adding bases such as pyridine, triethylamine, sodium hydroxide solution or alkali metal carbonates. The reactions can be carried out in wide temperature ranges. It has proved advantageous to operate in the temperature range from 0° C. to the boiling point of the solvent used. Examples of solvents employed are methylene chloride, THF, DMF, toluene, ethyl acetate, n-heptane, dioxane, and diethyl ether.

The hydrazines of the formula 2 can be prepared by known methods, for example by diazotization of the corresponding anilines and

subsequent reduction by known methods or by nucleophilic substitution of suitably substituted phenyl derivatives of the formula 6 (X=F, Cl, Br, l, OSO₂CF₃) with hydrazine hydrate. Such suitable phenyl derivatives may be nitro-substituted halobenzenes, such as fluoro- and chloronitrobenzenes, from which the compounds of the invention can be prepared by known methods at a suitable point in the synthetic route by reduction and reaction with acylating or alkylating agents such as, for example, acid chlorides, anhydrides, isocyanates, chloroformic esters, sulfonyl chlorides or alkyl and arylalkyl halides, or by reductive alkylation with aldehydes.

The effect of the compounds of the invention on HSL was tested using the following enzyme assay system:

Enzyme Preparation:

Preparation of Partially Purified HSL:

Isolated rat fat cells were obtained from epididymal adipose tissue from untreated male rats (Wistar, 220-250 g) by collagenase treatment according to published methods (e.g., S. Nilsson et al., Anal. Biochem. 158:399-407 (1986); G. Fredrikson et al., J. Biol. Chem. 256:6311-6320 (1981); H. Tornquist et al., J. Biol. Chem. 251:813-819 (1976)). The fat cells from 10 rats were washed three times by flotation with 50 ml each time of homogenization buffer (25 ml tris/HCl, pH 7.4, 0.25 M sucrose, 1 mM EDTA, 1 mM DTT, 10 μg/ml leupeptin, 10 μg/ml antipain, 20 μg/ml pepstatin) and finally taken up in 10 ml of homogenization buffer. The fat cells were homogenized in a Teflon-in-glass homogenizer (Braun-Melsungen) by 10 strokes at 1500 rpm and 15° C. The homogenate was centrifuged (Sorvall SM24 tubes, 5000 rpm, 10 min, 4° C.). The subnatant between the fatty layer at the top and the pellet was removed and the centrifugation was repeated. The subnatant resulting therefrom was recentrifuged (Sorvall SM24 tubes, 20000 rpm, 45 min, 4° C.). The subnatant was removed and mixed with 1 g of heparin-Sepharose (Pharmacia-Biotech, CL-6B, 5×washed with 25 mM tris/HCl, pH 7.4,150 mM NaCl). After the mixture had been incubated at 4° C. for 60 min (shaking at 15-min intervals), it was centrifuged (Sorvall SM24 tubes, 3000 rpm, 10 min, 4° C.). The supernatant was adjusted to pH 5.2 by adding glacial acetic acid and incubated at 4° C. for 30 min. The precipitates were collected by centrifugation (Sorvall SS34, 12000 rpm, 10 min, 4° C.) and suspended in 2.5 ml of 20 mM tris/HCl, pH 7.0,1 mM EDTA, 65 mM NaCl, 13% sucrose, 1 mM DTT, 10 μg/ml leupeptin/pepstatin/antipain. The suspension was dialyzed against 25 mM tris/HCl, pH 7.4, 50% glycerol, 1 mM DTT, 10 μg/ml leupeptin, pepstatin, antipain at 4° C. overnight and then loaded onto a hydroxy apatite column (0.1 g per 1 ml of suspension, equilibrated with 10 mM potassium phosphate, pH 7.0, 30% glycerol, 1 mM DTT). The column was washed with four volumes of equilibration buffer at a flow rate of 20 to 30 ml/h. The HSL was eluted with one volume of equilibration buffer containing 0.5 M potassium phosphate, and then dialyzed (see above) and concentrated 5- to 10-fold by ultrafiltration (Amicon Diaflo PM 10 filter) at 4° C. The partially purified HSL can be stored at −70° C. for 4 to 6 weeks.

Assay:

To prepare the substrate, 25-50 μCi of [³H]trioleoylglycerol (in toluene), 6.8 μmol of unlabeled trioleoylglycerol and 0.6 mg of phospholipids (phosphatidylcholine/phosphatidylinositol 3:1 w/v) were mixed, dried with N₂ and then taken up in 2 ml of 0.1 M KP_(i) (pH 7.0) by ultrasonic treatment (Branson 250, microtip, setting 1-2, 2×1 min at 1-min intervals). After addition of 1 ml of KP_(i) and renewed ultrasonic treatment (4×30 sec on ice in 30-sec intervals), 1 ml of 20% BSA (in KP_(i)) was added (final concentration of trioleoylglycerol 1.7 mM). For the reaction, 100 μl of substrate solution were pipetted into 100 μl of HSL solution (HSL prepared as above, diluted in 20 mM KP_(i), pH 7.0, 1 mM EDTA, 1 mM DTT, 0.02% BSA, 20 μg/ml pepstatin, 10 μg/ml leupeptin) and incubated at 37° C. for 30 min. Addition of 3.25 ml of methanol/chloroform/heptane (10:9:7) and of 1.05 ml of 0.1 M K₂CO₃, 0.1 M boric acid (pH 10.5) was followed by thorough mixing and finally centrifugation (800×g, 20 min). After phase separation, one equivalent of the upper phase (1 ml) was removed and the radioactivity was determined by liquid scintillation measurement.

Evaluation:

Substances were normally tested in four independent mixtures. The inhibition of the HSL enzymatic activity by a test substance was determined by comparison with an uninhibited control reaction. The IC₅₀ was calculated via an inhibition plot with at least 10 concentrations of the test substance. The data was analyzed using the software package GRAPHIT, Elsevier-BIOSOFT.

Selected compounds of the invention showed the following effect, as measured by this assay:

Compound of Example No. IC₅₀ (μM) 21 10 22 1 27 10 28 6 30 1 31 10 32 3 33 0.2 34 1 36 10 37 1 38 1 39 1 40 10 41 0.1 42 1 53 1 54 1 58 0.8 60 0.2 62 0.3 65 1 69 0.03 71 0.02 74 0.04 92 0.25 97 0.03 107  0.12 116  0.1 128  0.6 130  0.5 136  0.5 139  0.4 142  0.2 152  0.2 166  0.2 171  0.6

The following examples illustrate the preparation methods in detail without restricting them.

EXAMPLE 1

3-Methyl-4-nitrophenylhydrazine

5 g of hydrazine hydrate were slowly added dropwise to a solution of 15.9 g of 2-methyl-4-fluoronitrobenzene in 10 ml of N-methylpyrrolidone at room temperature, and the mixture was heated with stirring at 65° C. for 4 hours. The product was precipitated by adding 70 ml of water and was filtered off with suction and then recrystallized from isopropanol.

Yield:13.3 g m.p.: 138° C.

The following examples were prepared in an analogous way:

EXAMPLE 2

3-Fluoro-4-nitrophenylhydrazine

M.p.: 130° C.

EXAMPLE 3

2-Chloro-4-nitrophenylhydrazine

M.p.:144° C.

EXAMPLE 4

2-Methyl-4-nitrophenylhydrazine

M.p.:135° C.

EXAMPLE 5

3-(4-Fluorobenzyloxy)-2-nitrophenylhydrazine

M.p.:164° C.

The starting compound 2-fluoro-4-(4-fluorobenzyloxy)nitrobenzene (m.p.: 99° C.) was prepared by alkylation of 3-fluoro-4-nitrophenol with 4-fluorobenzyl chloride in DMF in the presence of potassium carbonate.

EXAMPLE 6

3-(4-Fluorobenzyloxy)-4-nitrophenylhydrazine (intermediate)

M.p.: 145° C.

EXAMPLE 7

4-(4-Chlorophenoxy)-3-nitroaniline

1.4 g of potassium carbonate were added to a solution of 1.29 g of 4-chlorophenol in 8 ml of DMF and, after stirring for 30 minutes, 1.6 g of 4-fluoro-3-nitroaniline were added, and the mixture was stirred at 100° C. for 3 hours. After cooling, 80 ml of water were added and, after brief stirring, the precipitate was filtered off with suction and dried in vacuo at 40° C.

Yield: 2.0 g; m.p.: 101° C.

EXAMPLE 8

4-(4-Chlorophenoxy)-3-nitrophenylhydrazine

A solution of 0.52 g of sodium nitrite in 5 ml of water was added dropwise to a stirred mixture consisting of 1.9 g of 4-(4-chlorophenoxy)-3-nitroaniline, 25 ml of concentrated hydrochloric acid and 25 ml of ethanol cooled to 0° C., and the mixture was then stirred at 0° C. for 60 min and subsequently added dropwise to a suspension of 8.5 g of tin dichloride dihydrate in 8 ml of concentrated HCl. The precipitate was filtered off with suction, washed with water, suspended in 200 ml of water under nitrogen and decomposed with 100 ml of 30% strength sodium hydroxide solution at 10-15° C. The oil formed was extracted by shaking with ethyl acetate and washed with water, and the organic phase was dried with sodium sulfate. The product was then precipitated with isopropanolic HCl, filtered off with suction and dried in vacuo.

Yield: 1.1 g; m.p.: 221° C.

EXAMPLE 9

Methyl N′-(4-nitro-2-methylphenyl)hydrazinoformate

0.43 ml of methyl chloroformate was cautiously added dropwise to a mixture consisting of 0.84 g of 2-methyl-4-nitrophenylhydrazine, 15 ml of NMP and 2 ml of pyridine while cooling in ice, and the mixture was then stirred for 2 hours while slowly warming to RT. After dilution with 50 ml of water, the mixture was stirred over night and the solid was dried in vacuo at 40° C.

Yield: 0.81 g; m.p.:153° C.

The following examples were prepared in an analogous way:

EXAMPLE 10

Methyl N′-(4-nitrophenyl)hydrazinoformate (intermediate)

M.p.: 179° C.

EXAMPLE 11

Methyl N′-(3-fluoro-4-nitrophenyl)hydrazinoformate

M.p.: 127.4° C.

EXAMPLE 12

Methyl N′-(3-methyl-4-nitrophenyl)hydrazinoformate

M.p.: 159° C.

EXAMPLE 13

Methyl N′-(2-chloro-4-nitrophenyl)hydrazinoformate

M.p.: 156° C.

EXAMPLE 14

Methyl N′-(3-(4-fluorobenzyloxy)-4-nitrophenyl)hydrazinoformate (intermediate)

M.p.: 166° C.

EXAMPLE 15

Methyl N′-(3-(4-fluorobenzyloxy)-2-nitrophenyl)hydrazinoformate

M.p.: 193° C.

EXAMPLE 16

Methyl N′-(4-(4-chlorophenoxy)-3-nitrophenyl)hydrazinoformate

M.p.: 147° C.

EXAMPLE 17

Methyl N′-(3-piperidino-4-nitrophenyl)hydrazinoformate (-)

M.p.: 131° C.

The latter compound and the compound of Example 18 were prepared by reacting methyl N′-(3-fluoro-4-nitrophenyl)hydrazinoformate with piperidine and N-benzyl-piperazine, respectively, in NMP at 80° C.

EXAMPLE 18

Methyl N′-(3-(N-benzylpiperazino)-4-nitrophenyl)hydrazinoformate

M.p.: 156° C.

EXAMPLE 19

5-Methoxy-3-(4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

2.5 g of methyl N′-(4-nitrophenyl)hydrazinoformate and 5 ml of pyridine were taken up in 15 ml of methylene chloride and, while stirring and cooling in ice, 3 ml of a 20% strength solution of phosgene in toluene were added dropwise. This mixture was left to stand at room temperature overnight and was diluted with a further 10 ml of methylene chloride and then washed 3 times with water. After drying over sodium sulfate, the mixture was concentrated in vacuo, and the product was purified by column chromatography (silica gel, solvents: methanol:methylene chloride=2:98) and recrystallized from isopropanol.

Yield:1.5 g m.p.: 151° C.

The following examples were prepared analogously to Example 4:

EXAMPLE 20

5-Methoxy-3-(3-methyl-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 112° C.

EXAMPLE 21

5-Methoxy-3-(4-(4-chlorophenoxy-3-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 22

5-Methoxy-3-(3-(4-fluorobenzyloxy)-2-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 99° C.

EXAMPLE 23

5-Methoxy-3-(2-methyl-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 111° C.

EXAMPLE 24

5-Methoxy-3-(3-(4-fluorobenzyloxy)-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 137° C.

EXAMPLE 25

5-Methoxy-3-(4-aminophenyl)-3H-(1,3,4)oxadiazol-2-one

A mixture consisting of 1.4 g of 5-methoxy-3-(4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one, 0.5 g of Pd/C and 20ml of methanol was hydrogenated under atmospheric pressure at room temperature until the calculated amount of hydrogen had been taken up. The catalyst was then filtered off, and the solution was concentrated in vacuo. The remaining semisolid residue was stirred with isopropanol and filtered off with suction.

Yield: 0.75g; m.p.: 85° C.

EXAMPLE 26

5-Methoxy-3-(2-amino-4-(4-fluorobenzyloxy)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 27

5-Methoxy-3-(3-amino-4-(4-chlorophenoxy)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 133° C.

EXAMPLE 28

5-Methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 114° C.

EXAMPLE 29

5-Methoxy-3-(4-amino-3-(4-fluorobenzyloxy)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 195° C.

EXAMPLE 30

5-Methoxy-3-(4-(4-chlorophenylacetylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

201 mg of 4-chlorophenylacetyl chloride were added dropwise to a mixture consisting of 200 mg of 5-methoxy-3-(4-aminophenyl)-3H-(1,3,4)oxadiazol-2-one, 20 ml of methylene chloride and 0.1 ml of pyridine cooled in ice, and the mixture was stirred at room temperature for 5 hours. Volatiles were removed in vacuo. The residue was stirred with water and the solid was filtered off with suction and dried at 40° C. in vacuo.

Yield: 318 mg; m.p.:161° C.

The following examples were prepared in an analogous way:

EXAMPLE 31:

5-Methoxy-3-(4-(4-chlorophenylacetylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 190° C.

EXAMPLE 32

5-Methoxy-3-(4-octanoylamino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 110° C.

EXAMPLE 33

5-Methoxy-3-(4-(4-heptylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 155° C.

EXAMPLE 34

5-Methoxy-3-(4-(4-butylphenylsulfonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 135° C.

EXAMPLE 35

5-Methoxy-3-(4-(4-chlorobutanoylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 137° C.

EXAMPLE 36

5-Methoxy-3-(4-pivaloylamino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 157° C.

EXAMPLE 3

5-Methoxy-3-(4-(4-chlorophenylsulfonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 147° C.

EXAMPLE 38

5-Methoxy-3-(4-(1-naphthylsulfonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 123° C.

EXAMPLE 39

5-Methoxy-3-(4-(2-phenylethenylsulfonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 129° C.

EXAMPLE 40

5-Methoxy-3-(4-(2,2,2-trifluoroethylsulfonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 151° C.

EXAMPLE 41

5-Methoxy-3-(4-(benzyloxycarbonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 115° C.

EXAMPLE 42

5-Methoxy-3-(4-(3,4-dichlorophenylaminocarbonylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 210° C.

The latter compound was obtained by reacting 5-methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with equimolar amounts of 3,4-dichlorophenyl isocyanate in toluene at 50° C.

EXAMPLE 43

5-Methoxy-3-(4-(4-chlorophenylsulfonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 169° C.

EXAMPLE 44

5-Methoxy-3-(4-(2-chlorophenylsulfonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 171° C.

EXAMPLE 45

5-Methoxy-3-(4-(3-chlorophenylsulfonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 141° C.

EXAMPLE 46

5-Methoxy-3-(4-(4-chlorophenylacetylamino)-3-(4-fluorobenzyloxy)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 167° C.

EXAMPLE 47

5-Methoxy-3-(4-benzylsulfonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 153° C.

EXAMPLE 48

5-Methoxy-3-(4-(-2-(4′-chlorobiphenyl)ethyl)sulfonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 165° C.

EXAMPLE 49

5-Methoxy-3-(4-isopropylsulfonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 190° C.

EXAMPLE 50

5-Methoxy-3-(4-dimethylamino-3-methylphenyl)-3H-(1,3,4)oxad iazol-2-one

M.p.: 71° C.

The latter compound was obtained by reacting 5-methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with paraformaldehyde/formic acid in DMF at room temperature and was purified by column chromatography (silica gel, ethyl acetate:n-heptane=1:1).

EXAMPLE 51

5-Methoxy-3-(4-(4-chlorobenzylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

The latter compound was obtained by reacting 5-methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with 4-chlorobenzaldehyde/sodium borohydride in methanol/methylene chloride at room temperature and was purified by column chromatography (silica gel, ethyl acetate:n-heptane=1:1).

EXAMPLE 52

5-Methoxy-3-(4-(2-oxopyrrolidin-1-yl)-3-methylphenyl)-3H-(1,3,4)oxad iazol-2-one

M.p.: oil

The latter compound was prepared by reacting 5-methoxy-3-(4-(4-chlorobutanoylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with sodium hydride in dioxane at room temperature and purifying the crude product by column chromatography (silica gel, methylene chloride:methanol=98:2).

EXAMPLE 53

5-Methoxy-3-(4-(4-oxopent-2-en-2-ylamino)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 143° C.

The latter compound was obtained by reacting 5-methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with equimolar amounts of acetylacetone in glacial acetic acid at 80° C. and was isolated by precipitation by adding water and filtration.

EXAMPLE 54

5-Methoxy-3-(4-(2,5-dimethylpyrrol-1-yl)-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

The latter compound was obtained by reacting 5-methoxy-3-(4-amino-3-methylphenyl)-3H-(1,3,4)oxadiazol-2-one with equimolar amounts of acetonylacetone in glacial acetic acid at 80° C. Working up took place by dilution with water, extraction by shaking with ethyl acetate and column chromatography (silica gel, methylene chloride) of the crude product obtained after concentration of the dried organic phase.

EXAMPLE 55

5-Methoxy-3-(3-(4-fluorobenzyloxy)-4-methylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 98° C.

The latter compound was obtained as a by-product of the hydrogenation of 5-methoxy-3-(3 -(4-fluorobenzyloxy)-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one with platinum dioxide as catalyst, in methanol, at room temperature under atmospheric pressure. Purification proceeded by column chromatography (silica gel, methylene chloride) after filtering off the catalyst and concentrating the reaction mixture.

The compounds of Examples 56-199 were prepared analogously to the above-mentioned examples.

EXAMPLE 56

5-Methoxy-3-(3-aminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 95° C.

EXAMPLE 57

5-Methoxy-3-(3-dibenzylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 71° C.

EXAMPLE 58

5-Methoxy-3-(3-benzylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 59

5-Methoxy-3-(4-(pyrid-2-yl)aminocarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 81° C.

EXAMPLE 60

5-Methoxy-3-(3-(4-fluorobenzyloxy)-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 61

5-Methoxy-3-(4-amino-2-methylphenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 62

5-Methoxy-3-(3-methyl-4-(2-chlorobenzyloxycarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 161° C.

EXAMPLE 63

5-Methoxy-3-(4-amino-2-chlorophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 126° C.

EXAMPLE 64

5-Methoxy-3-(2-chloro-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 92° C.

EXAMPLE 65

5-Methoxy-3-(2-methyl-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 112° C.

EXAMPLE 66

5-Methoxy-3-(2-methyl-4-(4-trifluoromethoxybenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 150° C.

EXAMPLE 67

5-Methoxy-3-(2-chloro-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 150° C.

EXAMPLE 68

5-Methoxy-3-(3-fluoro-4-nitrophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 127° C.

EXAMPLE 69

5-Methoxy-3-(4-(4-t-butylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 173° C.

EXAMPLE 70

5-Methoxy-3-(4-(4-chlorobenzyloxycarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 177° C.

EXAMPLE 71

5-Methoxy-3-(2-chloro-4-(4-heptylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 135° C.

EXAMPLE 72

5-Methoxy-3-(4-(3,4-dichlorobenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 200° C.

EXAMPLE 73

5-Methoxy-3-(4-(2-(4-chlorophenoxy)-2-methylpropionylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 153° C.

EXAMPLE 74

5-Ethoxy-3-(3-methyl-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 94° C.

EXAMPLE 75

5-isopropoxy-3-(3-methyl-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 119° C.

EXAMPLE 76

5-isopropoxy-3-(3-methyl-4-butyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M. p.: 114° C.

EXAMPLE 77

5-isopropoxy-3-(3-methyl-4-(3-chlorophenylaminocarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 201° C.

EXAMPLE 78

5-tert-Butoxy-3-(3-methyl-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 113° C.

EXAMPLE 79

5-Methoxy-3-(3-methyl-4-phenoxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 145° C.

EXAMPLE 80

5-Methoxy-3-(3-methyl-4-(pyrid-3-ylcarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 81

5-Methoxy-3-(3-methyl-4-(indan-2-ylaminocarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 206° C.

EXAMPLE 82

5-Methoxy-3-(3-methyl-4-(pyrid-3-ylmethylaminocarbonylamino)phenyl)-3H-(1,3, 4)oxadiazol-2-one

M.p.: 229° C.

EXAMPLE 83

5-Methoxy-3-(3-methyl-4-(pyrid-3-ylmethoxycarbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 232° C.

EXAMPLE 84

5-Methoxy-3-(3-fluoro-4-benzyloxycarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 85

5-Methoxy-3-(3-fluoro-4-(4-trifluoromethylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: oil

EXAMPLE 86

5-Methoxy-3-(3-benzyloxy-4-(4-trifluoromethylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 159° C.

EXAMPLE 87

5-Methoxy-3-(3-fluoro-4-(4-tert-butylbenzoylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 144° C.

EXAMPLE 88

5-Methoxy-3-(3-methyl-4-(2,2,2-trifluoroethoxycarbonylamino)phenyl)-3H-(1,3, 4)oxadiazol-2-one

M.p.: 141° C.

EXAMPLE 89

5-Methoxy-3-(3-methyl-4-piperidinocarbonylaminophenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 154° C.

EXAMPLE 90

5-Methoxy-3-(4-(6-methoxybenzofuran-2-yl-carbonylamino)phenyl)-3H-(1,3,4)oxadiazol-2-one

M.p.: 191° C.

Further examples of the invention were prepared by the processes described above and characterized by mass spectroscopy (M+1):

Example Mol. No. Chemical name: M + 1 wt.  91 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 362 361.4 yl)phenyl]-3-methyl-benzenesulfonamide  92 3,4-Dimethoxy-N-[4-(5-methoxy-2-oxo-[1,3, 408 407.4 4]oxadiazol-3-yl)-phenyl]benzenesulfon- amide  93 Quinoline-8-sulfonic acid [4-(5-methoxy-2- 399 398.4 oxo-[1,3,4]oxadiazol-3-yl)phenyl]amide  94 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 415 414.3 yl)phenyl]-5-nitro-isophthalic acid mono- methyl ester  95 3-(2-Chlorophenyl)-5-methylisoxazole-4- 427 426.8 carboxylic acid [4-(5-methoxy-2-oxo-[1,3, 4]oxadiazol-3-yl)phenyl]amide  96 3,3,3-Trifluoro-2-methoxy-N-[4-(5-methoxy- 424 423.3 2-oxo-[1,3,4]oxadiazol-3-yl)phenyl]-2- phenylpropionamide  97 2-Fluoro-N-[4-(5-methoxy-2-oxo-[1,3,4] 330 329.3 oxadiazol-3-yl)phenyl]-benzamide  98 Tetradecanoic acid [4-(5-methoxy-2-oxo-[1, 418 417.5 3,4]oxadiazol-3-yl)phenyl]amide  99 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 416 415.4 yl)phenyl]-2-phenethyl-benzamide 100 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 479 478.4 yl)phenyl]-2-(4-methoxyphenoxy)-5-nitro- benzamide 101 2-(4-Benzyloxyphenyl)-N-[4-(5-methoxy-2- 432 431.4 oxo-[1,3,4]oxadiazol-3-yl)phenyl]acetamide 102 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 492 491.5 yl)phenyl]-3,3,3-triphenylpropionamide 103 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 448 447.3 yl)phenyl]-3,5-bis-trifluoromethylbenzamide 104 4-Cyano-N-[4-(5-methoxy-2-oxo-[1,3,4] 337 336.3 oxadiazol-3-yl)phenyl]-benzamide 105 Nonanoic acid [4-(5-methoxy-2-oxo-[1,3,4] 348 347.4 oxadiazol-3-yl)phenyl]amide 106 Methyl 9-[4-(5-methoxy-2-oxo-[1,3,4] 406 405.4 oxadiazol-3-yl)phenyl-carbamoyl]nonanoate 107 Undecanoic acid [4-(5-methoxy-2-oxo-[1,3, 376 375.5 4]oxadiazol-3-yl)phenyl]amide 108 4-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 394 393.3 yl)phenylcarbamoyl]-benzenesulfonyl fluoride 109 11-Phenoxyundecanoic acid [4-(5-methoxy- 468 467.6 2-oxo-[1,3,4]-oxadiazol-3-yl)phenyl]amide 110 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 416 415.4 yl)phenyl]-2,3-diphenylpropionamide 111 4-Chloro-N-[4-(5-methoxy-2-oxo-[1,3,4] 360 359.8 oxadiazol-3-yl)phenyl]-2-methylbenzamide 112 6-Chloro-N-[4-(5-methoxy-2-oxo-[1,3,4] 347 346.7 oxadiazol-3-yl)phenyl]nicotinamide 113 5-Fluoro-N-[4-(5-methoxy-2-oxo-[1,3,4] 344 343.3 oxadiazol-3-yl)phenyl]-2-methylbenzamide 114 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 354 353.4 yl)phenyl]-2,4,6-trimethylbenzamide 115 N-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 388 387.4 yl)phenyl]-3-naphthalen-2-ylacrylamide 116 5-Oxo-5-phenylpentanoic acid [4-(5- 382 381.4 methoxy-2-oxo-[1,3,4]-oxadiazol-3-yl) phenyl]amide 117 3-(2,4-Dichlorobenzylsulfanyl)thiophene-2- 509 508.4 carboxylic acid [4-(5-methoxy-2-oxo-[1,3,4] oxadiazol-3-yl)phenyl]amide 118 2-Fluoro-N-[4-(5-methoxy-2-oxo-[1,3,4] 398 397.3 oxadiazol-3-yl)phenyl]-4-trifluoromethyl- benzamide 119 1-Hexyl-3-[3-(5-methoxy-2-oxo-[1,3,4] 335 334.4 oxadiazol-3-yl)phenyl]urea 120 1-(4-Bromophenyl)-3-[3-(5-methoxy-2-oxo- 406 405.2 [1,3,4]oxadiazol-3-yl)phenyl]urea 121 1-[3-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 357 356.3 yl)phenyl]-3-(2-methoxyphenyl)urea 122 Ethyl 2-[3-[3-(5-methoxy-2-oxo-[1,3,4]oxa- 427 426.4 diazol-3-yl)phenyl]-ureido]-3-phenyl- propionate 123 1-(2,6-Diisopropylphenyl)-3-[3-(5-methoxy- 411 410.5 2-oxo-[1,3,4]oxadiazol-3-yl)phenyl]urea 124 1-[3-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 363 362.4 yl)phenyl]-3-octylurea 125 1-(4-Fluorobenzyl)-3-[3-(5-methoxy-2-oxo- 359 358.3 [1,3,4]oxadiazol-3-yl)phenyl]urea 126 1-(2-Ethylphenyl)-3-[3-(5-methoxy-2-oxo- 355 354.4 [1,3,4]oxadiazol-3-yl)phenyl]urea 127 Ethyl 6-[3-[3-(5-methoxy-2-oxo-[1,3,4] 393 392.4 oxadiazol-3-yl)phenyl]-ureido]hexanoate 128 1-(2,6-Dimethoxyphenyl)-3-[3-(5-methoxy- 387 386.4 2-oxo-[1,3,4]oxadiazol-3-yl)phenyl]urea 129 5-Methoxy-3-[4-[(thiophen-3-ylmethyl) 304 303.3 amino]phenyl]-3H-[1,3,4]oxadiazol-2-one 130 4-[[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 437 436.3 yl)phenylamino]methyl]-benzonitrile tri- fluoroacetate 131 3-[4-(2-Bromo-4,5-dimethoxybenzylamino) 437 436.3 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol-2- one 132 3-[4-(3-Ethoxy-4-methoxybenzylamino) 486 485.4 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol- 2-one trifluoroacetate 133 Methyl 4-[[4-(5-methoxy-2-oxo-[1,3,4] 470 469.4 oxadiazol-3-yl)phenylamino]methyl]benzoate trifluoroacetate 134 4-[[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 356 355.3 yl)phenylamino]-methyl]phenyl acetate 135 5-Methoxy-3-[4-(pentafluorophenylmethyl- 388 387.3 amino)phenyl]-3H-[1,3,4]oxadiazol-2-one 136 3-[4-(4-Benzyloxybenzylamino)phenyl]-5- 518 517.5 methoxy-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 137 3-[4-(3,3-Dichlorononylamino)phenyl]-5- 517 516.3 methoxy-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 138 2-[[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 323 322.3 yl)phenylamino]-methyl]benzonitrile 139 3-[4-(Cyclohexylmethylamino)phenyl]-5- 304 303.4 methoxy-3H-[1,3,4]oxadiazol-2-one 140 5-Methoxy-3-[4-(2,3,5-trichlorobenzyl- 515 514.7 amino)phenyl]-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 141 3-[4-(5-Bromo-2-fluorobenzylamino) 509 508.2 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol-2- one trifiuoroacetate 142 3-[4-(4-Hexyloxybenzylamino)phenyl]-5- 512 511.5 methoxy-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 143 5-Methoxy-3-[4-[3-(3-trifluoromethyl- 572 571.4 phenoxy)benzylamino]-phenyl]-3H-[1,3, 4]oxadiazol-2-one trifluoroacetate 144 3-[4-[(2-Chloroquinolin-3-ylmethyl)amino] 497 496.8 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol-2- one trifluoroacetate 145 Methyl 3-methoxy-5-[[4-(5-methoxy-2-oxo- 501 500.4 [1,3,4]oxadiazol-3-yl)phenylamino]methyl] pyridine-2-carboxylate trifluoroacetate 146 4-[[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 454 453.5 yl)phenylamino]-methyl]phenyl benzenesulfonate 147 2-(2,6-Dimethyl-4-methylsulfanylphenoxy)- 416 415.5 N-[3-(5-methoxy-2-oxo-[1,3,4]oxadiazol-3- yl)phenyl]acetamide 148 1-(2,4-Difluorophenyl)-3-[4-(5-methoxy-2- 363 362.3 oxo-[1,3,4]oxadiazol-3-yl)phenyl]urea 149 1-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 419 418.4 yl)phenyl]-3-(4-phenoxyphenyl)urea 150 1-(2,6-Difluorophenyl)-3-[4-(5-methoxy-2- 363 362.3 oxo-[1,3,4]oxadiazol-3-yl)phenyl]urea 151 1-Butyl-3-[4-(5-methoxy-2-oxo-[1,3,4] 307 306.3 oxadiazol-3-yl)phenyl]urea 152 1-(2-Ethoxyphenyl)-3-[4-(5-methoxy-2-oxo- 371 370.4 [1,3,4]oxadiazol-3-yl)phenyl]urea 153 1-(2,6-Dibromo-4-fluorophenyl)-3-[4-(5- 503 502.1 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl) phenyl]urea 154 1-(4-Butoxyphenyl)-3-[4-(5-methoxy-2-oxo- 399 398.4 [1,3,4]oxadiazol-3-yl)phenyl]urea 155 1-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 411 410.3 yl)phenyl]-3-(4-trifluoromethoxyphenyl)urea 156 1-Benzyl-3-[4-(5-methoxy-2-oxo-[1,3,4] 341 340.3 oxadiazol-3-yl)phenyl]urea 157 1-(3-Fluorophenyl)-3-[4-(5-methoxy-2-oxo- 345 344.3 [1,3,4]oxadiazol-3-yl)phenyl]urea 158 Ethyl 6-[3-[4-(5-methoxy-2-oxo-[1,3,4] 393 392.4 oxadiazol-3-yl)phenyl]-ureido]hexanoate 159 1-Biphenyl-4-yl-3-[4-(5-methoxy-2-oxo-[1,3, 403 402.4 4]oxadiazol-3-yl)phenyl]urea 160 Butyl 2-[3-[4-(5-methoxy-2-oxo-[1,3,4] 427 426.4 oxadiazol-3-yl)phenyl]-ureido]benzoate 161 5-Methoxy-3-[3-(7-methoxy-3,7-dimethyl- 492 491.5 octylamino)phenyl]-3H-[1,3,4]oxadiazol-2- one trifluoroacetate 162 5-Methoxy-3-[3-[(thiophen-2-ylmethyl) 418 417.4 amino]phenyl]-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 163 3-(3-Hexylaminophenyl)-5-methoxy-3H-[1, 406 405.4 3,4]oxadiazol-2-one trifluoroacetate 164 5-Methoxy-3-[3-(3-phenylpropylamino) 440 439.4 phenyl]-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 165 5-Methoxy-3-(3-undecylaminophenyl)-3H- 476 475.5 [1,3,4]oxadiazol-2-one trifluoroacetate 166 5-Methoxy-3-[3-[(3-trifluoromethylphenoxy) 572 571.4 benzylamino]phenyl]-3H-[1,3,4]oxadiazol-2- one trifluoroacetate 167 3-[3-[(2-Chloroquinolin-3-ylmethyl)amino] 497 496.8 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol-2- one trifluoroacetate 168 4-[[3-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 586 585.5 yl)phenylamino]-methyl]phenyl 4-fluoro- benzenesulfonate trifluoroacetate 169 5-Methoxy-3-[3-(3,4,5-trifluorobenzylamino) 466 465.3 phenyl]-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 170 3-[3-(3,5-Bistrifluoromethylbenzylamino) 548 547.3 phenyl]-5-methoxy-3H-[1,3,4]oxadiazol-2- one trifluoroacetate 171 3-(3-Dec-4-enylaminophenyl)-5-methoxy- 460 459.5 3H-[1,3,4]oxadiazol-2-one trifluoroacetate 172 3-[3-(3-Cyclopentyl-2-phenethyloxybenzyl- 600 599.6 amino)phenyl]-5-methoxy-3H-[1,3,4] oxadiazol-2-one trifluoroacetate 173 4-[[3-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 437 436.3 yl)phenylamino]methyl]-benzonitrile trifluoroacetate 174 5-Methoxy-3-[3-[(6-methylpyridin-2- 427 426.3 ylmethyl)amino]phenyl]-3H-[1,3,4] oxadiazol-2-one trifluoroacetate 175 3-[3-(2-Benzyloxyethylamino)phenyl]-5- 456 455.4 methoxy-3H-[1,3,4]oxadiazol-2-one trifluoroacetate 176 3-[3-(2,6-Difluorobenzylamino)phenyl]-5- 448 447.3 methoxy-3H-[1,3,4]oxadiazol-2-one trifluoroacetate M.p. ° C. 177 Dodecanoic acid [4-(5-methoxy-2-oxo-[1,3,4]  93 oxadiazol-3-yl)phenyl]amide 178 Octadec-9-enoic acid [4-(5-methoxy-2-oxo-[1,3,4]  67 oxadiazol-3-yl)phenyl]-amide 179 2-Methoxyethyl [4-(5-methoxy-2-oxo-[1,3,4] 117 oxadiazol-3-yl)-2-methylphenyl]carbamate 180 1-(4-Hydroxycyclohexyl)-3-[4-(5-methoxy-2-oxo- 220 [1,3,4]oxadiazol-3-yl)-2-methylphenyl]urea 181 1,1-Dibutyl-3-[4-(5-methoxy-2-oxo-[1,3,4] Oil oxadiazol-3-yl)-2-methyl-phenyl]urea 182 5-Methoxybenzofuran-2-carboxylic acid [4-(5- 199 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)-2- methylphenyl]amide 183 4-Methylpiperazine-1-carboxylic acid [4-(5- Oil methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)-2- methylphenyl]amide 184 1-Methylpiperidin-4-yl [4-(5-methoxy-2-oxo-[1,3, 235 4]oxadiazol-3-yl)-2-methylphenyl]carbamate 185 Cyclohexyl [4-(5-methoxy-2-oxo-[1,3,4] 163 oxadiazol-3-yl)-2-methylphenyl]-carbamate 186 4-Benzylpiperidine-1-carboxylic acid [4-(5- 146 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)-2-methyl- phenyl]amide 187 1-(2-Diisopropylaminoethyl)-3-[4-(5- 136 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)-2- methylphenyl]urea 188 4-(2-{3-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3- 200 yl)-2-methylphenyl]-ureido}ethyl)benzenesulfon- amide 189 1-(1-Benzylpiperidin-4-yl)-3-[4-(5-methoxy-2- 198 oxo-[1,3,4]oxadiazol-3-yl)-2-methylphenyl]urea 190 1-(4-Isopropylphenyl)-3-[4-(5-methoxy-2-oxo-[1, 200 3,4]oxadiazol-3-yl)-2-methylphenyl]urea 191 2-{3-[4-(5-Methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)- 246 2-methylphenyl]ureido}-3-methylbutyric acid 192 1,2,3,4-Tetrahydronaphth-1-yl [4-(5-methoxy-2- 159 oxo-[1,3,4]oxadiazol-3-yl)-2-methylphenyl] carbamate 193 1-Phenylethyl [4-(5-methoxy-2-oxo-{1,3,4] Oil oxadiazol-3-yl)-2-methyl-phenyl]carbamate 194 4-Isopropylbenzyl [4-(5-methoxy-2-oxo-[1,3,4]  88 oxadiazol-3-yl)-2-methylphenyl]carbamate 195 4-Trifluoromethoxybenzyl [4-(5-methoxy-2-oxo-  82 [1,3,4]oxadiazol-3-yl)-2-methylphenyl]carbamate 196 3,5-Dichlorobenzyl [4-(5-methoxy-2-oxo-[1,3,4] 169 oxadiazol-3-yl)-2-methylphenyl]carbamate 197 Biphenyl-2-ylmethyl [4-(5-methoxy-2-oxo-[1,3,4] 138 oxadiazol-3-yl)-2-methylphenyl]carbamate 198 5-Chlorobenzofuran-2-carboxylic acid-[4-(5- 210 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)-2-methyl- phenyl]amide 199 5-Chlorobenzofuran-2-carboxylic acid [4-(5- 209 methoxy-2-oxo-[1,3,4]oxadiazol-3-yl)phenyl] amide 

We claim:
 1. Compounds of the formula 1

in which: R¹ is C₁-C₆-alkyl, C₃-C₉-cycloalkyl, wherein both groups are optionally substituted one or more times by phenyl, C₁-C₄-alkyloxy, S—C₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, and wherein phenyl is optionally substituted one or more times by halogen, C₁-C₄-alkyl, C₁-C₄-alkyloxy, nitro, CF₃; and R², R³, R⁴ and R⁵ independently of one another are hydrogen, halogen, nitro, C₁-C₄-alkyl, C₁-C₉-alkyloxy; C₆-C₁₀-aryl-C₁-C₄-alkyloxy, C₆-C₁₀-aryloxy, C₆-C₁₀-aryl, C₃-C₈-cycloalkyl or O—C₃-C₈-cycloalkyl, each of which is optionally substituted once, twice or three times by halogen, CF₃, C₁-C₄-alkyloxy or C₁-C₄-alkyl; 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR⁶-A-R⁷, with the proviso that R², R³, R⁴ and R⁵ are not simultaneously hydrogen, and at least one of the radicals R², R³, R⁴ or R⁵ is the radical 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl, or NR⁶-A-R⁷, and wherein: R⁶ is hydrogen, C₁-C₄-alkyl or C₆-C₁₀-aryl-C₁-C₄-alkyl, where aryl may be substituted by halogen, CF₃, C₁-C₈-alkyloxy or C₁-C₄-alkyl; A is a single bond, CO_(n), SO_(n), or CONH; n is 1 or 2; R⁷ is hydrogen; C₁-C₁₈-alkyl or C₂-C₁₈-alkenyl, wherein C₁-C₁₈-alkyl or C₂-C₁₈-alkenyl are optionally substituted one to three times by C₁-C₄-alkyl, halogen, CF₃, C₁-C₄-alkyloxy, N(C₁-C₄-alkyl)₂, —COOH, C₁-C₄-alkyloxycarbonyl, C₆-C₁₂-aryl, C₆-C₁₂-aryloxy, C₆-C₁₂-arylcarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy or oxo, wherein aryl is in turn optionally substituted by halogen, C₁-C₄-alkyl, aminosulfonyl or methylmercapto; C₆-C₁₀-aryl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl, C₆-C₁₀-aryl-C₂-C₆-alkenyl, C₆-C₁₀-aryl, biphenylyl, biphenylyl-C₁-C₄-alkyl, indanyl, each of which is optionally substituted once or twice by C₁-C₁₈-alkyl, C₁-C₁₈-alkyloxy, C₃-C₈-cycloalkyl, COOH, hydroxyl, C₁-C₄-alkylcarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, C₆-C₁₀-aryloxy, nitro, cyano, C₆-C₁₀-aryl, fluorosulfonyl, C₁-C₆-alkyloxycarbonyl, C₆-C₁₀-arylsulfonyloxy, pyridyl, NHSO₂-C₆-C₁₀-aryl, halogen, CF₃ or OCF₃, wherein alkyl is in turn optionally substituted by C₁-C₄-alkyloxycarbonyl, CF₃ or carboxyl, and aryl is also optionally substituted by halogen, CF₃ or C₁-C₄-alkyloxy; or the group Het-(CH₂)_(r)—, wherein r=0, 1, 2 or 3 and Het=a saturated or unsaturated 5-7-membered heterocycle, optionally benzo-fused and optionally substituted by C₁-C₄-alkyl, C₆-C₁₀-aryl, halogen, C₁-C₄-alkyloxy, C₁-C₄-alkyloxycarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkylmercapto or nitro, wherein the benzo-fused aryl is in turn optionally substituted by halogen, C₁-C₄-alkyloxy or CF₃ and the alkyl in arylalkyl is also optionally by methoxy and CF₃, and their pharmaceutically acceptable salts and acid addition salts.
 2. Compounds of the formula 1 as claimed in claim 1, in which R¹ is C₁-C₄-alkyl.
 3. Compounds of the formula 1 as claimed in claim 1, in which R¹ is methyl.
 4. Compounds of the formula 1 as claimed in claim 1, in which R⁵ is hydrogen.
 5. Compounds of the formula 1 as claimed in claim 1, in which R² is hydrogen, halogen, C₁-C₄-alkyl, C₁-C₉-alkyloxy or amino.
 6. Compounds of the formula 1 as claimed in claim 1, in which R³ is hydrogen, C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, which is optionally substituted in the aryl moiety by halogen, or is NR⁶-A-R⁷ wherein R⁶=hydrogen or benzyl, A=single bond and R⁷=C₆-C₁₀-aryl-C₁-C₄-alkyl, which is optionally substituted by halogen, CF₃, cyano, phenyl-C₁-C₄-alkyloxy, CF₃-phenoxy, C₅-C₈-cycloalkyl or fluorosulfonyloxy; C₁-Ci₂-alkyl, which is optionally substituted by C₁-C₄-alkyloxy, phenyl, CF₃ or phenyl-C₁-C₄-alkyloxy; C₂-C₁₂-alkenyl or the group Het-(CH₂)_(r)—, wherein r=0 or 1, and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl or halogen.
 7. Compounds of the formula 1 as claimed in claim 1, in which R⁴ is hydrogen, 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl, or C₆-C₁₀-aryl-C₁-C₄-alkyloxy, which is optionally substituted by halogen.
 8. Compounds of the formula 1 as claimed in claim 1, in which: R⁴ is NR⁶-A-R⁷, wherein R⁶=hydrogen or methyl, A=single bond and R⁷=hydrogen; C₁-C₁₂-alky, which is optionally substituted once or twice by halogen; C₂-C₁₈-alkenyl, which is optionally substituted once or twice by C₁-C₄-alkyl or C₁-C₄-alkyloxycarbonyl; C₆-C₁₀-aryl-C₁-C₄-alky, which is optionally substituted by halogen, C₁-C₆-alkyloxy, CF₃, cya no, C₅-C₆-cycloalkyl, C₁-C₄-alkyloxycarbonyl, C₆-C₁₀-aryl-C₁-C₄-alkyl, C₆-C₁₀-aryl-C₁-C₄-alkyloxy, wherein aryl is further optionally substituted by halogen or CF₃; C₅-C₈-cycloalkyl-C₁-C₄-alkyl ; or the group Het-(CH₂)r—, wherein r=1, 2 or 3 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally substituted by halogen, C₁-C₄-alkyloxy or C₁-C₄-alkyloxycarbonyl.
 9. Compounds of the formula 1 as claimed in claim 1, in which: R⁴ is NR⁶-A-R⁷ wherein R⁶=hydrogen, A=—CO— and R⁷ C₁-C₁₈-alkyl, which is optionally substituted by halogen, phenyl, phenoxy, phenylcarbonyl or C₁-C₄-alkyloxycarbonyl, wherein phenoxy is optionally substituted by methyl, halogen or methylmercapto; C₂-C₁₈-alkenyl, which is optionally substituted by C₆-C₁₀-aryl; C₆-C₁₀-aryl, which is optionally substituted by halogen, C₁-C₈-alkyl, phenyl-C₁-C₄-alkyl, CF₃, OCF₃, fluorosulfonyl, C₁-C₄-alkyloxycarbonyl, phenoxy, wherein aryl is optionally substituted by C₁-C₄-alkyloxy; C₆-C₁₀-aryl-C₁-C₄-alkyl, wherein alkyl is optionally substituted by methoxy or CF₃ and aryl by halogen; or the group Het-(CH₂)_(r)—, wherein r=0 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl, halogen, C₁-C₄-alkyloxy, halophenyl or halobenzylmercapto, wherein benzo-fused aryl is optionally substituted by halogen or methoxy.
 10. Compounds of the formula 1 as claimed in claim 1, in which: R⁴ is NR⁶-A-R⁷, wherein R⁶=hydrogen, A=—CO₂— and R⁷=C₁-C₁₈-alkyl, which is substituted by CF₃ or phenyl; C₆-C₁₀-aryl; C₆-C₁₀-aryl-C₁-C₄-alkyl, which is substituted by C₁-C₄-alkyl, halogen, CF₃ or OCF₃, benzyloxy or phenyl; or the group Het-(CH₂)_(r)—, wherein r=0 or 1 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally benzo-fused and optionally substituted by C₁-C₄-alkyl or benzyl.
 11. Compounds of the formula 1 as claimed in claim 1, in which: R⁴ is NR⁶-A-R, wherein R⁶=hydrogen, A=—SO₂— and R⁷=C₁-C₆-alky, which is optionally substituted by CF₃; C₂-C₄-alkenyl, which is optionally substituted by phenyl; C₆-C₁₀-aryl, which is optionally substituted by C₁-C₆-alkyl, halogen, C₁-C₄-alkyloxy or benzyl; biphenylyl-C₁-C₄-alkyl substituted by halogen; or the group Het-(CH₂)_(r)—, wherein r=0 and Het=a saturated or unsaturated 5-7-membered heterocycle.
 12. Compounds of the formula 1 as claimed in claim 1, in which: R⁴ is NR⁶-A-R⁷, wherein R⁶=hydrogen, A=—CO—NH— and R⁷=C₁-C₁₀-alkyl, which is optionally substituted by C₁-C₄-alkyloxycarbonyl, N(C₁-C₄-alkyl)₂ or phenyl, which is in turn optionally substituted by halogen or aminosulfonyl; C₆-C₁₀-aryl, which is optionally substituted by C₁-C₆-alkyl, C₁-C₆-alkyloxy, C₁-C₆-alkyloxycarbonyl, phenoxy, OCF₃, benzyl or pyridyl, wherein alkyl is optionally substituted by C₁-C₄-alkyloxycarbonyl or carboxyl; C₅-C₈-cycloalky, which is optionally substituted by hydroxyl, or indanyl; or the group Het-(CH2)r—, wherein r=0 or 1 and Het=a saturated or unsaturated 5-7-membered heterocycle, which is optionally substituted by benzyl.
 13. A process for preparing compounds of the formula 1 as claimed in any one of claims 1 to 12, comprising the steps of:

reacting hydrazines of the formula 2 with chloroformic esters of the formula 3 or other reactive carbonic ester derivatives in which R¹, R², R³, R⁴ and R⁵ are as defined in claim 1 to give the compounds of the formula 4, acylating the compounds of the formula 4 with phosgene, carbonyldiimidazole, diphosgene or triphosgene, to give the compounds of the formula 5, and cyclizing the compounds of the formula 5 into the compounds of the formula
 1. 14. A process according to claim 13 further comprising the step of reacting said compounds of formula 1 with a suitable agent to form pharmaceutically acceptable salts or acid addition salts.
 15. A process according to claim 13, further comprising the step of chemical modification of the radicals R₂-R₅ by reduction of nitro to amino radicals, acylation or alkylation.
 16. A process according to claim 15 further comprising the step of reacting said compounds of formula 1 with a suitable agent to form pharmaceutically acceptable salts or acid addition salts.
 17. A pharmaceutical composition for treating non-insulin-dependent diabetes mellitus or diabetic syndrome, comprising at least one of the compounds of formula 1 as claimed in any one of claims 1 to
 12. 18. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 1. 19. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 is claimed in claim
 2. 20. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 3. 21. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 4. 22. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 5. 23. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 6. 24. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 7. 25. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 8. 26. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 9. 27. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 10. 28. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 11. 29. A method of inhibiting hormone-sensitive lipase, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 12. 30. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 1. 31. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 2. 32. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 3. 33. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 4. 34. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 5. 35. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 6. 36. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 7. 37. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 8. 38. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 9. 39. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 10. 40. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 11. 41. A method of treating non-insulin dependent diabetes mellitus or diabetic syndrome, comprising administering to a patient in need thereof at least one compound of the formula 1 as claimed in claim
 12. 